Towards the lowest efficacious dose (toledo): results of a multicenter non-inferiority randomized open-label controlled trial assessing tocilizumab or abatacept injection spacing in rheumatoid arthritis patients in remission - Archive ouverte HAL Accéder directement au contenu
Communication Dans Un Congrès Année : 2019

Towards the lowest efficacious dose (toledo): results of a multicenter non-inferiority randomized open-label controlled trial assessing tocilizumab or abatacept injection spacing in rheumatoid arthritis patients in remission

(1, 2, 3) , (4) , (5) , (6, 7) , (8) , (9) , (10) , (11, 12) , (13, 14) , (15, 16) , (17) , (18, 7) , (19) , (20) , (21) , (22, 7) , (23) , (24, 25) , (26) , (27, 7) , (28) , (29, 30) , (31, 32) , (7) , (33, 7) , (34) , (7) , (35, 7) , (36, 37) , (38, 39) , (40) , (7) , (3, 2, 41) , (3, 2, 41) , (1)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

Dates et versions

hal-03606082 , version 1 (11-03-2022)

Identifiants

Citer

Joanna Kedra, Philippe Dieude, Hubert Marotte, Alexandre Lafourcade, Emilie Ducourau, et al.. Towards the lowest efficacious dose (toledo): results of a multicenter non-inferiority randomized open-label controlled trial assessing tocilizumab or abatacept injection spacing in rheumatoid arthritis patients in remission. Annual European Congress of Rheumatology (EULAR), Jun 2019, Madrid, Spain. pp.715-716, ⟨10.1136/annrheumdis-2019-eular.5060⟩. ⟨hal-03606082⟩
43 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More